Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

MadeMed vs Dr. Gillis' Wellness Center

Two GLP-1 desks, one scoreboard. We put MadeMed and Dr. Gillis' Wellness Center head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 8 · Grade B

MadeMed

Visit MadeMed Full brief →
vs
No. 103 · Grade C

Dr. Gillis' Wellness Center

Visit Dr. Gillis' Wellness Center Full brief →

The verdict

MadeMed takes this head-to-head.

MadeMed scores 86 to 72 on our six-factor Brief Score — Publishes a price for every dose of every route — which makes it easy to brief, and expensive if you stay low.

That doesn't make Dr. Gillis' Wellness Center a bad call — it's best for patients wanting sublingual odt glp-1 tablets or a needle-free weight-loss option. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
92
36
Supply Reliability
84
76
Transparency
94
88
Access Breadth
76
86
Clinical Oversight
84
84
Track Record
82
78
MadeMedBrief Score 86 · 72Dr. Gillis' Wellness Center

Price, coverage & the tracker

MadeMedDr. Gillis' Wellness Center
Brief Score86/100 (B)72/100 (C)
Semaglutide$239/mo injectable · $219/mo sublingual (quarterly)From $149/mo (starting dose, compounded)
Tirzepatide$399/mo injectable · $299/mo sublingual (quarterly)Not disclosed
Coverage40 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

MadeMed: Publishes one price per route that holds at every dose — the cleanest dose-to-price mapping we track.

Dr. Gillis' Wellness Center: New to the tracker on 1 August 2026. The published line reads From $149/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.